ArticleMolecular cancer therapeutics2024

TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma.

Hiroyuki Nishiyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.